JP2008514639A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008514639A5 JP2008514639A5 JP2007533754A JP2007533754A JP2008514639A5 JP 2008514639 A5 JP2008514639 A5 JP 2008514639A5 JP 2007533754 A JP2007533754 A JP 2007533754A JP 2007533754 A JP2007533754 A JP 2007533754A JP 2008514639 A5 JP2008514639 A5 JP 2008514639A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally substituted
- alkynyl
- acyl
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 38
- -1 sulfonate ester Chemical class 0.000 claims description 35
- 150000001875 compounds Chemical class 0.000 claims description 30
- 125000000623 heterocyclic group Chemical group 0.000 claims description 26
- 125000000304 alkynyl group Chemical group 0.000 claims description 23
- 229920002554 vinyl polymer Polymers 0.000 claims description 22
- 125000002252 acyl group Chemical group 0.000 claims description 20
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 20
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 19
- 229910052717 sulfur Inorganic materials 0.000 claims description 18
- 125000003342 alkenyl group Chemical group 0.000 claims description 16
- 229910052760 oxygen Inorganic materials 0.000 claims description 15
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 14
- 125000000262 haloalkenyl group Chemical group 0.000 claims description 14
- 125000000232 haloalkynyl group Chemical group 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 150000001350 alkyl halides Chemical class 0.000 claims description 13
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 13
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 11
- 239000001257 hydrogen Substances 0.000 claims description 11
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 11
- 125000001651 cyanato group Chemical group [*]OC#N 0.000 claims description 9
- 125000004122 cyclic group Chemical group 0.000 claims description 9
- 125000001072 heteroaryl group Chemical group 0.000 claims description 9
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 claims description 9
- 229910019142 PO4 Inorganic materials 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 8
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims description 8
- 125000005843 halogen group Chemical group 0.000 claims description 8
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 8
- 239000010452 phosphate Substances 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 125000004434 sulfur atom Chemical group 0.000 claims description 8
- 125000003282 alkyl amino group Chemical group 0.000 claims description 7
- 150000001540 azides Chemical class 0.000 claims description 7
- 125000001261 isocyanato group Chemical group *N=C=O 0.000 claims description 7
- 101100294115 Caenorhabditis elegans nhr-4 gene Proteins 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 241000710831 Flavivirus Species 0.000 claims description 4
- 241000711557 Hepacivirus Species 0.000 claims description 4
- 241000710778 Pestivirus Species 0.000 claims description 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 125000005140 aralkylsulfonyl group Chemical group 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 235000014633 carbohydrates Nutrition 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 235000012000 cholesterol Nutrition 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 4
- 150000002632 lipids Chemical group 0.000 claims description 4
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 150000003904 phospholipids Chemical class 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 150000003413 spiro compounds Chemical class 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 150000001721 carbon Chemical class 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 150000003871 sulfonates Chemical class 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 208000015181 infectious disease Diseases 0.000 claims 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 150000002148 esters Chemical class 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- 229940024606 amino acid Drugs 0.000 claims 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 125000002837 carbocyclic group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 2
- 239000000758 substrate Substances 0.000 claims 2
- ZZKNRXZVGOYGJT-VKHMYHEASA-N (2s)-2-[(2-phosphonoacetyl)amino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)CP(O)(O)=O ZZKNRXZVGOYGJT-VKHMYHEASA-N 0.000 claims 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 claims 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims 1
- YYVYAPXYZVYDHN-UHFFFAOYSA-N 9,10-phenanthroquinone Chemical compound C1=CC=C2C(=O)C(=O)C3=CC=CC=C3C2=C1 YYVYAPXYZVYDHN-UHFFFAOYSA-N 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 108060004795 Methyltransferase Proteins 0.000 claims 1
- 101710163270 Nuclease Proteins 0.000 claims 1
- 229940099408 Oxidizing agent Drugs 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 108091034057 RNA (poly(A)) Proteins 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 1
- 101800001838 Serine protease/helicase NS3 Proteins 0.000 claims 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 1
- 229960003805 amantadine Drugs 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- ZVSKZLHKADLHSD-UHFFFAOYSA-N benzanilide Chemical class C=1C=CC=CC=1C(=O)NC1=CC=CC=C1 ZVSKZLHKADLHSD-UHFFFAOYSA-N 0.000 claims 1
- 239000003613 bile acid Substances 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 239000002777 nucleoside Substances 0.000 claims 1
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 claims 1
- 239000007800 oxidant agent Substances 0.000 claims 1
- NAYYNDKKHOIIOD-UHFFFAOYSA-N phthalamide Chemical compound NC(=O)C1=CC=CC=C1C(N)=O NAYYNDKKHOIIOD-UHFFFAOYSA-N 0.000 claims 1
- 239000000419 plant extract Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229960000329 ribavirin Drugs 0.000 claims 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- QPILZZVXGUNELN-UHFFFAOYSA-M sodium;4-amino-5-hydroxynaphthalene-2,7-disulfonate;hydron Chemical compound [Na+].OS(=O)(=O)C1=CC(O)=C2C(N)=CC(S([O-])(=O)=O)=CC2=C1 QPILZZVXGUNELN-UHFFFAOYSA-M 0.000 claims 1
- 229940031439 squalene Drugs 0.000 claims 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims 1
- 150000003457 sulfones Chemical class 0.000 claims 1
- 150000003548 thiazolidines Chemical class 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 229940046009 vitamin E Drugs 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003459 sulfonic acid esters Chemical class 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical group [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61308504P | 2004-09-24 | 2004-09-24 | |
| PCT/US2005/034786 WO2006037028A2 (en) | 2004-09-24 | 2005-09-26 | Methods and compositions for treating flaviviruses, pestiviruses and hepacivirus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008514639A JP2008514639A (ja) | 2008-05-08 |
| JP2008514639A5 true JP2008514639A5 (https=) | 2008-11-13 |
Family
ID=36119563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007533754A Pending JP2008514639A (ja) | 2004-09-24 | 2005-09-26 | フラビウイルス、ペスチウイルス及びヘパシウイルスの感染症を治療するための方法及び組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20080280850A1 (https=) |
| EP (1) | EP1804811A4 (https=) |
| JP (1) | JP2008514639A (https=) |
| KR (1) | KR20070073805A (https=) |
| CN (1) | CN101072570A (https=) |
| AU (1) | AU2005289517A1 (https=) |
| BR (1) | BRPI0515896A (https=) |
| CA (1) | CA2581523A1 (https=) |
| IL (1) | IL182061A0 (https=) |
| NO (1) | NO20072055L (https=) |
| RU (1) | RU2007115419A (https=) |
| WO (1) | WO2006037028A2 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| EP1736478B1 (en) | 2000-05-26 | 2015-07-22 | IDENIX Pharmaceuticals, Inc. | Methods and compositions for treating flaviviruses and pestiviruses |
| CN1678326A (zh) | 2002-06-28 | 2005-10-05 | 埃迪尼克斯(开曼)有限公司 | 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷 |
| NZ537662A (en) | 2002-06-28 | 2007-10-26 | Idenix Cayman Ltd | 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| LT1576138T (lt) | 2002-11-15 | 2017-06-26 | Idenix Pharmaceuticals Llc | 2`-šakoti nukleozidai derinyje su interferonu ir flaviviridae mutacija |
| AU2003300901A1 (en) | 2002-12-12 | 2004-06-30 | Idenix (Cayman) Limited | Process for the production of 2'-branched nucleosides |
| HUE029877T2 (en) | 2003-05-30 | 2017-04-28 | Gilead Pharmasset Llc | Modified fluorinated nucleoside analogues |
| CN101023094B (zh) | 2004-07-21 | 2011-05-18 | 法莫赛特股份有限公司 | 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备 |
| US8492539B2 (en) | 2004-09-14 | 2013-07-23 | Gilead Pharmasset Llc | Preparation of 2′-fluoro-2′-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| GB2471806B (en) | 2008-04-03 | 2012-12-19 | Spring Bank Pharmaceuticals Inc | Compositions and methods for treating viral infections |
| AU2009329872B2 (en) | 2008-12-23 | 2016-07-07 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
| NZ593649A (en) | 2008-12-23 | 2013-11-29 | Gilead Pharmasset Llc | Nucleoside analogs |
| PA8855601A1 (es) | 2008-12-23 | 2010-07-27 | Forformidatos de nucleósidos | |
| TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| SG184324A1 (en) | 2010-03-31 | 2012-11-29 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| US8563530B2 (en) | 2010-03-31 | 2013-10-22 | Gilead Pharmassel LLC | Purine nucleoside phosphoramidate |
| CA2818853A1 (en) | 2010-11-30 | 2012-06-07 | Gilead Pharmasset Llc | 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus |
| EP2709613B2 (en) | 2011-09-16 | 2020-08-12 | Gilead Pharmasset LLC | Methods for treating hcv |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| CN103833812A (zh) * | 2012-11-23 | 2014-06-04 | 中国人民解放军军事医学科学院毒物药物研究所 | 吡嗪衍生物及其医药用途 |
| EP2950786B1 (en) | 2013-01-31 | 2019-11-27 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
| ES2734209T3 (es) | 2013-08-06 | 2019-12-04 | Imago Biosciences Inc | Inhibidores de KDM1A para el tratamiento de enfermedades |
| PT3038601T (pt) | 2013-08-27 | 2020-06-30 | Gilead Pharmasset Llc | Formulação combinada de dois compostos antivirais |
| CN105732748B (zh) * | 2014-12-12 | 2019-01-01 | 浙江医药股份有限公司新昌制药厂 | 一种核苷酸类似物及其制备方法、以及含有核苷酸类似物的药物组合物及其应用 |
| CA2976350C (en) | 2015-02-12 | 2023-09-19 | Hugh Young Rienhoff, Jr. | Kdm1a inhibitors for the treatment of disease |
| CN111194306B (zh) | 2016-08-16 | 2023-05-16 | 伊美格生物科学公司 | 用于制备kdm1a抑制剂的方法和过程 |
| EP3790867B1 (en) | 2018-05-11 | 2024-03-27 | Imago Biosciences Inc. | Kdm1a inhibitors for the treatment of disease |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5134066A (en) * | 1989-08-29 | 1992-07-28 | Monsanto Company | Improved probes using nucleosides containing 3-dezauracil analogs |
| ATE294185T1 (de) * | 2000-02-16 | 2005-05-15 | Toyama Chemical Co Ltd | Neue pyrazin-derivate oder salze davon, pharmazeutische zusammensetzungen, die die derivate oder deren salze enthalten und intermediäre zur herstellung der derivate |
| KR100894167B1 (ko) * | 2001-08-14 | 2009-04-22 | 토야마 케미칼 컴퍼니 리미티드 | 신규의 바이러스 증식저해 ·살바이러스방법 및 신규의피라진뉴클레오티드 ·피라진뉴클레오시드 유사체 |
| JP2005527499A (ja) * | 2002-02-13 | 2005-09-15 | メルク エンド カムパニー インコーポレーテッド | ヌクレオシド化合物を用いてオルトポックスウイルスの複製を阻害する方法 |
| WO2003072757A2 (en) * | 2002-02-28 | 2003-09-04 | Biota, Inc. | Nucleotide mimics and their prodrugs |
| US20040063658A1 (en) * | 2002-05-06 | 2004-04-01 | Roberts Christopher Don | Nucleoside derivatives for treating hepatitis C virus infection |
| WO2003105770A2 (en) * | 2002-06-17 | 2003-12-24 | Merck & Co., Inc. | Carbocyclic nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| EP1572945A2 (en) * | 2002-06-27 | 2005-09-14 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| TW200500375A (en) * | 2002-06-28 | 2005-01-01 | Idenix Cayman Ltd | Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae |
| CN1678326A (zh) * | 2002-06-28 | 2005-10-05 | 埃迪尼克斯(开曼)有限公司 | 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷 |
| JP4398631B2 (ja) * | 2002-07-12 | 2010-01-13 | 富山化学工業株式会社 | 新規なピラジン誘導体またはその塩並びにそれらを含有する抗ウイルス剤 |
| EP1556399A4 (en) * | 2002-07-16 | 2007-09-26 | Merck & Co Inc | Nucleoside derivatives as inhibitors of RNA-dependent viral RNA polymerase |
| EP1572097A4 (en) * | 2002-09-30 | 2010-02-17 | Smithkline Beecham Corp | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF INFECTIONS WITH THE HEPATITIS C-VIRUS |
| LT1576138T (lt) * | 2002-11-15 | 2017-06-26 | Idenix Pharmaceuticals Llc | 2`-šakoti nukleozidai derinyje su interferonu ir flaviviridae mutacija |
-
2005
- 2005-09-26 WO PCT/US2005/034786 patent/WO2006037028A2/en not_active Ceased
- 2005-09-26 AU AU2005289517A patent/AU2005289517A1/en not_active Abandoned
- 2005-09-26 CN CNA2005800404057A patent/CN101072570A/zh active Pending
- 2005-09-26 EP EP05813010A patent/EP1804811A4/en not_active Withdrawn
- 2005-09-26 CA CA002581523A patent/CA2581523A1/en not_active Abandoned
- 2005-09-26 US US11/884,414 patent/US20080280850A1/en not_active Abandoned
- 2005-09-26 BR BRPI0515896-6A patent/BRPI0515896A/pt not_active Application Discontinuation
- 2005-09-26 RU RU2007115419/04A patent/RU2007115419A/ru not_active Application Discontinuation
- 2005-09-26 KR KR1020077009174A patent/KR20070073805A/ko not_active Withdrawn
- 2005-09-26 JP JP2007533754A patent/JP2008514639A/ja active Pending
-
2007
- 2007-03-20 IL IL182061A patent/IL182061A0/en unknown
- 2007-04-20 NO NO20072055A patent/NO20072055L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008514639A5 (https=) | ||
| RU2007115419A (ru) | Способы и композиции для лечения флавивирусов, пестивирусов и гепацивируса | |
| CA2490191A1 (en) | Modified 2' and 3' -nucleoside prodrugs for treating flaviviridae infections | |
| JP2007501185A5 (https=) | ||
| RU2006105640A (ru) | Аналоги пуриновых нуклеозидов для лечения flaviviridae, включая гепатит с | |
| JP2004533401A5 (https=) | ||
| CA2954751C (en) | Indoles for use in influenza virus infection | |
| RU2428428C9 (ru) | Серусодержащие соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с | |
| Abdou et al. | Phosphinic acids: current status and potential for drug discovery | |
| JP2009504764A5 (https=) | ||
| RU2005141176A (ru) | Модифицированые фторированные аналоги нуклеозида | |
| JP2009504763A5 (https=) | ||
| RU2012132218A (ru) | Соединения и фармацевтические композиции для лечения вирусных инфекций | |
| JP2005519916A5 (https=) | ||
| JP2004513881A5 (https=) | ||
| JP2019507774A5 (https=) | ||
| JP2002539128A5 (https=) | ||
| JP2008509166A5 (https=) | ||
| JP2014520822A5 (https=) | ||
| RU2004110719A (ru) | Зздабиторы протеаз, расщепляющих за пролином | |
| JP2013056886A5 (https=) | ||
| JP2017505314A5 (https=) | ||
| SI3106463T1 (en) | Compounds of substituted pyrazolo (1,5-) pyrimidine as inhibitors of TRK kinase | |
| PL409123A1 (pl) | Związki, ich zastosowanie i kompozycje do leczenia wirusowego zapalenia wątroby typu C | |
| HUP0100950A2 (hu) | Ciklusos aminovegyületek, alkalmazásuk gyógyászati készítmények előállítására és a vegyületeket tartalmazó gyógyászati készítmények |